(Q37389177)

20 August 2017

1 reference

title

Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses (English)

1 reference

20 August 2017

0 references

1 reference

1 reference

4

Giovanni Passalacqua

1 reference

20 August 2017

Giorgio Walter Canonica

series ordinal

5

object named as

Giorgio Walter Canonica

1 reference

20 August 2017

Enrico Compalati

1

1 reference

20 August 2017

Martin Penagos

series ordinal

2

1 reference

20 August 2017

Francesco Tarantini

series ordinal

3

1 reference

20 August 2017

language of work or name

1 reference

1 January 2009

1 reference

Annals of Allergy, Asthma & Immunology

20 August 2017

published in

1 reference

20 August 2017

volume

102

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

22-28

1 reference

Evidence based medicine: an approach to clinical problem-solving

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Evidence based medicine: what it is and what it isn't

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

A critical appraisal of 'evidence-based medicine' in allergy and asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Clinical guidelines: developing guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Meta-analysis: principles and procedures

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Allergic rhinitis and its impact on asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Efficacy and safety of sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

[Specific immunotherapy (hyposensitization) in allergic rhinoconjunctivitis. Meta-analysis of effectiveness and side effects]

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Sublingual immunotherapy for allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Allergen immunotherapy for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Allergen injection immunotherapy for seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Allergic rhinitis and its impact on asthma update: allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Allergen immunotherapy: where is it now?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Sublingual immunotherapy for asthma: need for high quality meta-analyses to prove the concept

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

New insights into the mechanisms of allergen-specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Mechanisms of immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Grading quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960103-2

7 January 2021

10.1016/S1081-1206(10)60103-2

Identifiers

DOI

1 reference

20 August 2017

1 reference